Publication:
Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors

Simple item page
dc.contributor.authorGranberg, Kirsi J.
dc.contributor.authorRaita, Annina
dc.contributor.authorLehtinen, Birgitta
dc.contributor.authorTiihonen, Aliisa M.
dc.contributor.authorKesseli, Juha
dc.contributor.authorAnnala, Matti
dc.contributor.authorRodriguez-Martinez, Alejandra
dc.contributor.authorNordfors, Kristiina
dc.contributor.authorZhang, Wei
dc.contributor.authorVisakorpi, Tapio
dc.contributor.authorNykter, Matti
dc.contributor.authorHaapasalo, Hannu K.
dc.date.accessioned2022-11-28T11:41:11Z
dc.date.available2022-11-28T11:41:11Z
dc.date.issued2020
dc.description.abstractDeregulation of fibroblast growth factor receptor (FGFR) signaling is tightly associated with numerous human malignancies, including cancer. Indeed, FGFR inhibitors are being tested as anti-tumor drugs in clinical trials. Among gliomas, FGFR3 fusions occur in IDH wild-type diffuse gliomas leading to high FGFR3 protein expression and both, FGFR3 and FGFR1, show elevated expression in aggressive ependymomas. The aim of this study was to uncover the expression of FGFR1 and FGFR3 proteins in choroid plexus tumors and to further characterize FGFR-related as well as other genetic alterations in FGFR3 expressing tumors. Expression levels of FGFR1 and FGFR3 were detected in 15 choroid plexus tumor tissues using immunohistochemistry of tissue microarrays and 6 samples were subjected to whole mount FGFR3 staining. Targeted sequencing was used for deeper molecular analysis of two FGFR3 positive cases. Moderate expression of FGFR1 or FGFR3 was evidenced in one third of the studied choroid plexus tumors. Targeted sequencing of a choroid plexus carcinoma and an atypical choroid plexus papilloma, both with moderate-to-strong FGFR3 expression, revealed lack of protein-altering mutations or fusions in FGFR1 or FGFR3, but TP53 was altered in both tumors. FGFR3 and FGFR1 proteins are expressed in a subpopulation of choroid plexus tumors. Further studies using larger cohorts of patients will allow identification of the clinicopathological implications of FGFR1 and FGFR3 expression in choroid plexus tumors.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.identifier.citationHistology and Histopathology Vol. 35, nº7 (2020)
dc.identifier.doihttps://doi.org/10.14670/HH-18-180
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/126023
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectTissue microarrayes
dc.subjectDeep sequencinges
dc.subjectFGFR gene fusiones
dc.subjectImmunohistochemical staininges
dc.subjectBrain tumores
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología
dc.titleModerate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumorses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Granberg-35-673-680-2020.pdf
Size:
17.52 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.35, nº7 (2020)